MAN & SCIENCE
0837.403.770 · rovalta.com · 23/09/2026
ACTIVE
MAN & SCIENCE
Financial year 2025 · closed on 31/12/2025
Net result
-3,3 M €
+73.8% YoY
Gross margin
-2,2 M €
-0.2% YoY
Equity
2,4 M €
-57.8% YoY
Workforce
7,6 ETP
+31.0% YoY
Overview
What does MAN & SCIENCE do?
MAN & SCIENCE is a Public limited company incorporated in 2011. Its main activity is: Manufacture of medical and dental instruments and supplies. Its registered office is in Liège. It employs on average 7,6 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0837.403.770
Incorporation
29/06/2011
Legal form
Public limited company
Registered office
Boulevard de Patience et Beaujonc 3 box 24
4000 Liège · WallonieSee on map
4000 Liège · WallonieSee on map
Contributed capital
22 880 772,81 €
Latest accounts
31/12/2025
Average workforce
7,6 ETP
Activities (NACE)
Joint committees (1)
- 200
Signals
Solid equityHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 14 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||
| Gross margin | -2,2 M € | -0.2% | -2,2 M € | -274% | 1,3 M € | +135% | -3,6 M € | -2478% | 152,6 k € | +146% | -333,1 k € | -1196% | -25,7 k € | -49.9% | -17,1 k € | -695% | -2,2 k € | +75.3% | -8,7 k € | +8.7% | -9,5 k € | +27.6% | -13,2 k € | -159% | -5,1 k € | +52.7% | -10,8 k € |
| EBITDA | -3,1 M € | -5.3% | -3 M € | -595% | 601 k € | +114% | -4,2 M € | -1234% | -312,6 k € | +17.5% | -379 k € | -1355% | -26,1 k € | -48.9% | -17,5 k € | -377% | -3,7 k € | +60.1% | -9,2 k € | +7.8% | -10 k € | +26.3% | -13,5 k € | -148% | -5,5 k € | +52.4% | -11,4 k € |
| Operating result | -3,7 M € | -12.5% | -3,3 M € | -839% | 440,8 k € | +111% | -4,2 M € | -1217% | -317,9 k € | +16.8% | -382,3 k € | -1200% | -29,4 k € | -41.1% | -20,8 k € | -468% | -3,7 k € | +60.1% | -9,2 k € | +7.8% | -10 k € | +26.3% | -13,5 k € | -148% | -5,5 k € | +52.4% | -11,4 k € |
| Net result | -3,3 M € | +73.8% | -12,7 M € | -2773% | 475,9 k € | +111% | -4,2 M € | -2008% | -199,1 k € | +48.0% | -383 k € | -60052% | -636,8 € | +97.0% | -21,5 k € | -412% | -4,2 k € | +63.4% | -11,5 k € | -9.6% | -10,5 k € | +29.1% | -14,7 k € | -170% | -5,5 k € | +51.1% | -11,2 k € |
| Balance sheet | |||||||||||||||||||||||||||
| Equity | 2,4 M € | -57.8% | 5,8 M € | -56.4% | 13,2 M € | +3.7% | 12,8 M € | +553% | 2 M € | -9.2% | 2,2 M € | +12335% | -17,6 k € | -3.8% | -17 k € | -477% | 4,5 k € | -48.2% | 8,7 k € | -56.9% | 20,1 k € | -34.2% | 30,6 k € | -32.5% | 45,3 k € | -10.8% | 50,8 k € |
| Total assets | 5,4 M € | -29.2% | 7,6 M € | -44.9% | 13,8 M € | -1.6% | 14 M € | +581% | 2,1 M € | -33.4% | 3,1 M € | +462% | 550,8 k € | -26.3% | 747,8 k € | +189% | 259,1 k € | +958% | 24,5 k € | -8.3% | 26,7 k € | -16.6% | 32 k € | -33.0% | 47,8 k € | -6.2% | 50,9 k € |
| Cash | 1,1 M € | -79.2% | 5,2 M € | +755% | 604,3 k € | -88.0% | 5 M € | +160% | 1,9 M € | -29.6% | 2,8 M € | +1060% | 237,6 k € | -49.9% | 474,8 k € | +2276% | 20 k € | -11.8% | 22,6 k € | -9.6% | 25 k € | -17.9% | 30,5 k € | -34.5% | 46,5 k € | -1.3% | 47,2 k € |
| Debts | 3 M € | +60.2% | 1,8 M € | +222% | 571,6 k € | -55.0% | 1,3 M € | +1072% | 108,4 k € | -88.5% | 942,4 k € | +65.8% | 568,4 k € | -25.7% | 764,6 k € | +200% | 254,6 k € | +1512% | 15,8 k € | +141% | 6,6 k € | +359% | 1,4 k € | -40.2% | 2,4 k € | +2296% | 99,8 € |
| Other | |||||||||||||||||||||||||||
| Workforce | 7,6 ETP | +31.0% | 5,8 ETP | – | – | – | – | – | – | – | – | – | – | – | – | ||||||||||||
Estimate
Indicative valuation
As an indication, this company is worth
between 1 M€ and 2,5 M€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2025 · 4 active · 26 ended
Active mandates
Ended mandates
At this address
Other companies at this address
| Company | CBE no. |
|---|---|
Abscint● Active | 0749.828.410 |
AMPACIMON● Active | 0827.990.317 |
Amyl Therapeutics● Active | 0758.775.372 |
BECARV● Bankrupt | 0840.777.885 |
BE.SPINE● Active | 1013.110.857 |
CEFALY Technology● Active | 0870.578.661 |
DERMAX● Active | 0667.730.677 |
DIANOSIC● Active | 1034.558.646 |
DW Cefaly Holding● Active | 0725.837.241 |
| 1023.778.481 | |
EXO Biologics● Active | 0732.982.379 |
ExoXpert● Active | 1003.807.666 |
Hirundo Biosciences● Active | 0681.855.065 |
HolyFox Invest● Active | 1010.693.181 |
Hyloris● Active | 0669.738.676 |
Hyloris Developments● Active | 0542.737.368 |
Hyloris Pharmaceuticals● Active | 0674.494.151 |
Hyloris Therapeutics● Active | 1025.029.385 |
LEGIAPARK● Active | 0728.589.170 |
ONCORADIOMICS● Active | 0662.719.440 |
Financials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 30/06/2026 | 10/10/2025 | 31/01/2025 | 31/08/2023 | 06/05/2022 | 11/06/2021 |
| General meeting | 30/06/2026 | 09/10/2025 | 31/01/2025 | 04/07/2023 | 27/04/2022 | 01/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
14 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 30/06/2026 | 30/06/2026 | French | |
| Abridged model | 31/12/2024 | 09/10/2025 | 10/10/2025 | French | |
| Micro model | 31/12/2023 | 31/01/2025 | 31/01/2025 | French | |
| Micro model | 31/12/2022 | 04/07/2023 | 31/08/2023 | French | |
| Micro model | 31/12/2021 | 27/04/2022 | 06/05/2022 | French | |
| Micro model | 31/12/2020 | 01/06/2021 | 11/06/2021 | French | |
| Abridged model | 31/12/2019 | 29/06/2020 | 31/07/2020 | French | |
| Micro model | 31/12/2018 | 28/06/2019 | 31/10/2019 | French | |
| Micro model | 31/12/2017 | 29/06/2018 | 31/08/2018 | French | |
| Micro model | 31/12/2016 | 05/06/2017 | 31/07/2017 | French | |
| Abridged model | 31/12/2015 | 06/06/2016 | 28/09/2016 | French | |
| Abridged model | 31/12/2014 | 01/06/2015 | 26/08/2015 | French | |
| Abridged model | 31/12/2013 | 02/06/2014 | 30/07/2014 | French | |
| Abridged model | 31/12/2012 | 01/06/2013 | 23/08/2013 | French |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 1 M€ and 2,5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2025 · 4 active · 26 ended
Active mandates
Ended mandates
Shareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Capital / shares11/03/2026CAPITAL, ACTIONS
- Mandates06/10/2025DEMISSIONS, NOMINATIONS
- Capital / shares31/12/2024CAPITAL, ACTIONS
- Mandates14/11/2024DEMISSIONS, NOMINATIONS
- Mandates16/05/2024DEMISSIONS, NOMINATIONS
- Capital / shares23/02/2023STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Mandates25/08/2022DEMISSIONS, NOMINATIONS
- Mandates30/05/2022STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-3,3 M €↑
- 2024Annual accounts 2024-12,7 M €↓
- 2023Annual accounts 2023475,9 k €↑
- 2022Annual accounts 2022-4,2 M €↓
- 2021Annual accounts 2021-199,1 k €↑
- 2020Annual accounts 2020-383 k €↓
- 2019Annual accounts 2019-636,8 €↑
- 2018Annual accounts 2018-21,5 k €↓
- 2017Annual accounts 2017-4,2 k €↑
- 2016Annual accounts 2016-11,5 k €↓
- 2015Annual accounts 2015-10,5 k €↑
- 2014Annual accounts 2014-14,7 k €↓
- 2013Annual accounts 2013-5,5 k €↑
- 2012Annual accounts 2012-11,2 k €
- 29/06/2011IncorporationPublic limited company